TCB 008
Alternative Names: Gamma delta T cell lymphocyte - TC Biopharm; TCB-008; unmodified expanded gamma delta T cell LymphocytesLatest Information Update: 28 May 2025
At a glance
- Originator TC BioPharm
- Developer Queen Mary University of London; TC BioPharm
- Class Anti-inflammatories; Antineoplastics; Antivirals; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
- Preclinical Mucositis
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in United Kingdom (IV, Injection)
- 16 Jan 2025 TC BioPharm plans a preclinical studies for Influenza A virus H1N1 subtype
- 11 Dec 2024 TC BioPharm has partnered with CareDx for pharmacokinetic monitoring of TCB008 in the ACHIEVE clinical trial for Acute Myeloid Leukemia and Myelodysplastic Syndrome .